A glucose-responsive controlled release of insulin system based on enzyme multilayers-coated mesoporous silica particles

Zhao, Wenru; Zhang, Hongti; He, Qianjun; Li, Yongsheng; Gu, Jinlou; Li, Liang; Li, Hua; Shi, Jianlin

doi:10.1039/c1cc12740c

Cited by 114 publications

(85 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peppas and coworkers also applied pH-sensitive hydrogels to synthesize glucose-responsive insulin delivery, where the hydrogels swells or shrinks in response to changing pH to adjust insulin release in a glucose-mediated manner (Hassan et al, 1997; Podual et al, 2000). Based on this concept, several groups have developed glucose-responsive closed-loop insulin delivery systems that incorporate pH-sensitive materials over the last decades (Di et al, 2015; Gordijo et al, 2010; Gu et al, 2013b; Kang and Bae, 2003; Zhao et al, 2011). …”

Section: Glucose-responsive Closed-loop Insulin Delivery Systemsmentioning

confidence: 99%

Advances in bioresponsive closed-loop drug delivery systems

Zhang

Yan

et al. 2018

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Controlled drug delivery systems are able to improve efficacy and safety of therapeutics by optimizing the duration and kinetics of release. Among them, closed-loop delivery strategies, also known as self-regulated administration, have proven to be a practical tool for homeostatic regulation, by tuning drug release as a function of biosignals relevant to physiological and pathological processes. A typical example is glucose-responsive insulin delivery system, which can mimic the pancreatic beta cells to release insulin with a proper dose at a proper time point by responding to plasma glucose levels. Similar self-regulated systems are also important in the treatment of other diseases including thrombosis and bacterial infection. In this review, we survey the recent advances in bioresponsive closed-loop drug delivery systems, including glucose-responsive, enzyme-activated, and other biosignal-mediated delivery systems. We also discuss the future opportunities and challenges in this field.

show abstract

Section: Glucose-responsive Closed-loop Insulin Delivery Systemsmentioning

confidence: 99%

Advances in bioresponsive closed-loop drug delivery systems

Zhang

Yan

et al. 2018

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…0.25 to 0.3 μM of MSN was capable of delivering a therapeutic dose of insulin in a glucose-responsive manner. The prospect of a dual delivery system is an exciting one, and has led to an increase in interest in MSNs for insulin delivery 37, 52, 66, 70 . However, the modification of insulin with gluconic acid raises questions about the bioavailability of the drug once released from the MSN.…”

Section: Nanotechnology Enabled Closed-loop Insulin Deliverymentioning

confidence: 99%

Recent advances in nanotechnology for diabetes treatment

DiSanto

Subramanian

2015

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Nanotechnology in diabetes research has facilitated the development of novel glucose measurement and insulin delivery modalities which hold the potential to dramatically improve quality of life for diabetics. Recent progress in the field of diabetes research at its interface with nanotechnology is our focus. In particular, we examine glucose sensors with nanoscale components including metal nanoparticles and carbon nanostructures. The addition of nanoscale components commonly increases glucose sensor sensitivity, temporal response, and can lead to sensors which facilitate continuous in vivo glucose monitoring. Additionally, we survey nanoscale approaches to “closed-loop” insulin delivery strategies which automatically release insulin in response to fluctuating blood glucose levels. “Closing the loop” between blood glucose level (BGL) measurements and insulin administration by removing the requirement of patient action holds the potential to dramatically improve the health and quality of life of diabetics. Advantages and limitations of current strategies, as well as future opportunities and challenges are also discussed.

show abstract

“…27b An insulin delivery system responsive to glucose was described by Shi and co-workers, which used enzyme GOx. 28 MSNs with a pore size of ca. 12 nm were synthesised and pores were loaded with insulin.…”

Section: Glucose Triggered Releasementioning

confidence: 99%